-
Mashup Score: 0
Srikala Sridhar joins Sam Chang in discussing long-term follow-up from the JAVELIN Bladder 100 trial of avelumab first-line maintenance for advanced urothelial carcinoma. The JAVELIN-100 study was conducted on patients with metastatic urothelial carcinoma who had received frontline platinum-based chemotherapy and achieved a disease response. These patients were then randomized to receive either…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 2Long-Term Follow-up from the JAVELIN Bladder 100 Trial - Srikala Sridhar - 10 month(s) ago
Srikala Sridhar joins Sam Chang in discussing long-term follow-up from the JAVELIN Bladder 100 trial of avelumab first-line maintenance for advanced urothelial carcinoma. The JAVELIN-100 study was conducted on patients with metastatic urothelial carcinoma who had received frontline platinum-based chemotherapy and achieved a disease response. These patients were then randomized to receive either…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
Long-term follow-up from the #JAVELIN Bladder 100 Trial. @kalasri3 @pmcancercentre joins @UroCancerMD @VUMCurology to discuss these results on UroToday > https://t.co/zaCwLPc0aS @EMDSerono https://t.co/hwjkztd2G7
-
-
Mashup Score: 0ASCO 2023: Long-Term Safety of Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma in the JAVELIN Bladder 100 Trial - 11 month(s) ago
ASCO 2023 long term safety profile of Avelumab as a first-line maintenance, JAVELIN Bladder 100 trial, which evaluated avelumab first-line (1L) maintenance for advanced urothelial carcinoma (aUC).
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
Long-term safety of avelumab first-line maintenance for advanced urothelial carcinoma in the #JAVELIN Bladder 100 trial. Presented by @OncoBellmunt @DanaFarber_GU. #ASCO23 written coverage by @tchandra_uromd @UCDavisUrology > https://t.co/u7B46loz1r @ASCO https://t.co/LIIbQ2eLU5
-
-
Mashup Score: 1Long-Term Follow-up from the JAVELIN Bladder 100 Trial - Srikala Sridhar - 11 month(s) ago
Srikala Sridhar joins Sam Chang in discussing long-term follow-up from the JAVELIN Bladder 100 trial of avelumab first-line maintenance for advanced urothelial carcinoma. The JAVELIN-100 study was conducted on patients with metastatic urothelial carcinoma who had received frontline platinum-based chemotherapy and achieved a disease response. These patients were then randomized to receive either…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
Long-term follow-up from the #JAVELIN Bladder 100 Trial. @kalasri3 @pmcancercentre joins @UroCancerMD @VUMCurology to discuss these results on UroToday > https://t.co/zaCwLPbslk @EMDSerono https://t.co/hH5yYzhQeJ
-
-
Mashup Score: 0Long-Term Follow-up from the JAVELIN Bladder 100 Trial - Srikala Sridhar - 12 month(s) ago
Srikala Sridhar joins Sam Chang in discussing long-term follow-up from the JAVELIN Bladder 100 trial of avelumab first-line maintenance for advanced urothelial carcinoma. The JAVELIN-100 study was conducted on patients with metastatic urothelial carcinoma who had received frontline platinum-based chemotherapy and achieved a disease response. These patients were then randomized to receive either…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
Long-term follow-up from the #JAVELIN Bladder 100 Trial. @kalasri3 @pmcancercentre joins @UroCancerMD @VUMCurology to discuss these results on UroToday > https://t.co/zaCwLPbslk @EMDSerono https://t.co/udBkYahBKI
-
-
Mashup Score: 0
AUA 2023, JAVELIN Bladder 100 trial, best supportive care (BSC), Avelumab, advanced urothelial carcinoma, bladder cancer, 1L chemotherapy, 2L anticancer therapy, platinum containing chemotherapy, gemcitabine, cisplatin, carboplatin.
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
Avelumab 1L maintenance for advanced #UrothelialCarcinoma: Long-term outcomes from #JAVELIN Bladder 100 in subgroups defined by response to 1L chemotherapy. Presented by Shilpa Gupta, MD @ClevelandClinic. #AUA23 coverage by @rksayyid > https://t.co/7EuvtTC6PO @AmerUrological https://t.co/daR9SUcKkJ
-
-
Mashup Score: 0
Srikala Sridhar joins Sam Chang in discussing long-term follow-up from the JAVELIN Bladder 100 trial of avelumab first-line maintenance for advanced urothelial carcinoma. The JAVELIN-100 study was conducted on patients with metastatic urothelial carcinoma who had received frontline platinum-based chemotherapy and achieved a disease response. These patients were then randomized to receive either…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
Long-term follow-up from the #JAVELIN Bladder 100 Trial. @kalasri3 @pmcancercentre joins @UroCancerMD @VUMCurology to discuss these results on UroToday > https://t.co/zaCwLPbslk @EMDSerono https://t.co/TvYTdPpqrY
-
-
Mashup Score: 0
ASCO GU 2023, C-Reactive Protein, Avelumab plus Axitinib, Advanced Renal Cell Carcinoma, JAVELIN Renal 101, IMDC risk, kidney cancer.
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
C-reactive protein as a predictive marker for outcomes with avelumab + axitinib in patients with poor-risk adv #RenalCellCarcinoma: Exploratory analysis from #JAVELIN Renal 101. Presented by @YoshihikoTomita. @ASCO #GU23 written coverage by @zklaassen_md > https://t.co/Kgpa2sOZ5f https://t.co/NLWJiD5NGu
-
-
Mashup Score: 4
Were you unable to attend ASCO GU 2023? Get all of the groundbreaking research, new guidelines, and the latest advances in urologic medicine you missed.
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
Avelumab 1L maintenance for adv #UrothelialCarcinoma: Long-term follow-up from #JAVELIN Bladder 100 in subgroups defined by 1L chemotherapy regimen and analysis of OS from start of 1L chemotherapy @kalasri3 @pmcancercentre #GU23 > https://t.co/tnIL5gfl0d @tchandra_uromd https://t.co/yO2Z4BhgdI
-
-
Mashup Score: 0Long-Term Outcomes from JAVELIN Bladder 100 - Cora Sternberg - 1 year(s) ago
Cora Sternberg joins Alicia Morgans in discussing subgroup analyses of the phase 3 JAVELIN Bladder 100 trial which demonstrated that first-line avelumab maintenance + best supportive care (BSC) significantly prolonged overall survival compared to BSC alone in patients with advanced urothelial carcinoma that had not progressed during initial induction treatment with platinum-based chemotherapy….
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
Long-term outcomes from #JAVELIN Bladder 100. @cnsternberg @WCMEnglanderIPM joins @CaPsurvivorship @DanaFarber to discuss data presented at #ASCO22 examining subgroup analyses and long-term outcomes in a conversation on UroToday > https://t.co/wCyXr5GKJU https://t.co/8pJIUm4Hk8
-
Long-term follow-up from the #JAVELIN Bladder 100 Trial. @kalasri3 @pmcancercentre joins @UroCancerMD @VUMCurology to discuss these results on UroToday > https://t.co/zaCwLPbslk @EMDSerono https://t.co/W5ucTuExmf